Bexagliflozin

Bexagliflozin

Clinical data
Trade names	Brenzavvy, Bexacat
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Bexagliflozin
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
CAS Number	1118567-05-7
PubChem CID	25195624
DrugBank	DB12236
ChemSpider	26609013
UNII	EY00JF42FV
KEGG	D10865
ChEMBL	ChEMBL1808388
Chemical and physical data
Formula	C24H29ClO7
Molar mass	464.94 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
InChI InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1 Key:BTCRKOKVYTVOLU-SJSRKZJXSA-N

Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth.

Medical uses

Bexagliflozin is indicated to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.

Research

A 96-week phase 2 clinical study of adults with type 2 diabetes showed that bexagliflozin monotherapy provided a durable, clinically meaningful improvement of glycemic control, with a substantial reduction in weight and blood pressure, but no increase in the rate of significant adverse events. In a clinical study of patients with type 2 diabetes and stage 3a/3b chronic kidney disease, bexagliflozin was well tolerated and shown to reduce hemoglobin A1c levels, body weight, systolic blood pressure and albuminuria.

Veterinary uses

The data from two six-month field studies and an extended use field study demonstrated that bexagliflozin was over 80% effective in improving glycemic control in cats with diabetes mellitus.

Bexagliflozin, sold under the brand name Bexacat, is an antidiabetic medication used to improve glycemic control in cats with diabetes. Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species. It was approved for medical use in the United States in December 2022. Bexacat is sponsored by Increvet Inc., based in Boston, Massachusetts. Elanco licensed development and commercialization rights for bexagliflozin from Bexcafe, an affiliate of Increvet.

Further reading

• Benedict SL, Mahony OM, McKee TS, Bergman PJ (January 2022). "Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus". Canadian Journal of Veterinary Research. 86 (1): 52–58. PMC 8697324. PMID 34975223.
• Zhang W, Li X, Ding H, Lu Y, Stilwell GE, Halvorsen YD, et al. (May 2020). "Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans". Xenobiotica. 50 (5): 559–569. doi:10.1080/00498254.2019.1654634. PMID 31432741. S2CID 201115043.

External links

• "Bexagliflozin". Drug Information Portal. U.S. National Library of Medicine.